7/102 sources · 2 publishersUpdated Oct 21, 10:37 UTC
TD Cowen lifts Moderna price target to $90 from $40
TD Cowen increased its price target for Moderna Inc. to $90, up from $40, while keeping a Hold rating. The firm also raised its estimate for Moderna’s peak internal profit to about $3.4 billion in 2035, reflecting expected commercial opportunities in melanoma and non‑small‑cell lung cancer. Moderna’s shares were trading around $242 at the time of the announcement.
Why it matters
TD Cowen says the higher target is based on a discounted cash‑flow model that incorporates the new profit estimate, which could lift the stock’s valuation for investors. The revised target may influence market sentiment and trading activity in Moderna.
Key facts
- 1TD Cowen raised its price target for Moderna to $90 from $40. investing.com
- 2The new target is based on a discounted cash‑flow analysis. investing.com
- 3TD Cowen increased its estimate for peak internal profit to approximately $3.4 billion in 2035, up from $830 million. investing.com
- 4Moderna’s shares were trading at $242.08. marketscreener.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.